Cardioprotective Effects with Fenofibrate in Type 2 Diabetes Patients1
Patients with type 2 diabetes (T2D) possess a considerably higher risk of cardiovascular morbidity and mortality. A study has found that the use of fenofibrate not only offers cardioprotective benefits, but also minimises the risks of cardiac and all-cause deaths in patients with T2D. Among 63,727 patients with T2D aged 40 to 79 years, 5,057 patients who received fenofibrate solely were compared to 5,057 patients who received neither fenofibrate nor omega-3 fatty acid over a median follow-up of 3 years. The primary endpoint, which involves a composite of myocardial infarction, stroke, percutaneous coronary revascularisation and cardiac death, was significantly lower in fenofibrate users. Cardiac death, all-cause death and stroke were remarkably lower in the fenofibrate group. The most pronounced cardiovascular benefits were demonstrated in the patient group who received the longest duration of fenofibrate and were sustained consistently among different patient subgroups. These findings appear to lay the groundwork for improving the cardiovascular outcomes in patients with T2D.
References
1 Jo SH, et al. Diabetes Care. 2021;dc201533.
